To develop a product strategy leveraging existing FDA 510K cleared radio Frequency technology to minimize regulatory risk.
Xinetix implemented previously FDA cleared and proven RF circuit topology as the core of the CK system. This approach facilitated rapid FDA 510K approval. Hal Walbrink joined the Board of Directors and assisted in raising the first capital investment.
Xinetix provided technical support in the science of RF induced thermal tissue effects to advance continued product development.
